It’s well-known that randomized controlled trials (RCTs) are the most trusted method for life sciences companies to study the efficacy of new treatments. But RCTs are expensive and time-consuming, and oftentimes the data isn’t leveraged after the trial ends. So what does the future hold for clinical trial design? Can the costs of RCTs be reduced? And how can predictive analytics help make trials and trial design more efficient?
In this article in Applied Clinical Trials, ZS’s Venkat Sethuraman was tapped to share his perspective on emerging trends in the clinical design space, and how those trending concepts could improve clinical trial design without undermining RCTs.
ZS is a professional services firm that works side by side with companies to help develop and deliver products that drive customer value and company results. We leverage our deep industry expertise, leading-edge analytics, technology and strategy to create solutions that work in the real world. With more than 35 years of experience and 8,000-plus ZSers in more than 25 offices worldwide, we are passionately committed to helping companies and their customers thrive. To learn more, visit www.zs.com or follow us on Twitter and LinkedIn.